Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.98 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.50 |
| ▸ | AR | P10275 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770186 | 0.99 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL6888773 | 0.84 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL7483385 | 0.81 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL3873977 | 0.77 | PGR (0.69) | PGRNR3C1NR3C2AR | |
| SCHEMBL3870555 | 0.77 | PGR (0.69) | PGRNR3C1NR3C2AR | |
| SCHEMBL6770069 | 0.72 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL27475124 | 0.72 | PGR (0.60) | PGRNR3C1NR3C2AR | |
| SCHEMBL27545111 | 0.71 | PGR (0.71) | PGRNR3C1NR3C2AR | |
| SCHEMBL4093560 | 0.70 | PGR (1.00) | PGRNR3C1 | |
| SCHEMBL7487504 | 0.70 | PGR (0.55) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693103-B2 | CONTRACEPTION, TREATMENT OF FIBROIDS, ANTICARCINOGENIC AND -TUMOR AGENTS (ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER), AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY; BENIGN PROSTATIC HYPERTROPHY; ADENOCARCINOMAS | WYETH | 2004-02-17 | — | — | US | disclosed |
| US-6498154-B1 | CONTRACEPTION; PROGESTATIONAL ACTIVE LEVONORGESTREL AND AN ANTIPROGESTIN COMPOUND | WYETH | 2002-12-24 | — | — | US | disclosed |
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2002-07-18 | — | — | US | disclosed |
| US-6358948-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS AGAINST BREAST, PITUITARY, OVARIAN, ENDOMETRIUM, AND PROSTATE CANCER; BENIGN PROSTATIC HYPERPLASIA; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | PGR, NR3C1, NR3C2 | PGR 1/4885NR3C1 2/4885NR3C2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.